Search - tctmd.com

Displaying 541 - 560 of 571

Sort: Relevancy | Date

Presentation TVT 2013

Transcatheter Closure of Incomplete Left Atrial Appendage Occlsuion (Previous Watchman LAA Occluder) - Implantation of a 2nd Generation ACP (Amulet) Device

Presenter: Simon Cheung Chi Lam

June 14, 2013

Presentation TVT 2013

Ad-hoc TAVI, Ad-hoc Coronary Stenting, and Ad-hoc LAA Closure

Presenter: Fabian Nietlispach

June 13, 2013

Presentation TCT Russia 2013

LAA Closure Devices - Technique Description and Emerging Data

Presenter: Horst Sievert

June 09, 2013

Presentation

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

Presenter: M. Urena

May 28, 2013

Presentation

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

Presenter: Vivek Y. Reddy

May 14, 2013

Presentation Fellows 2013

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: Mark Reisman

April 17, 2013

Presentation

LAA Closure with the Watchman Device in Patients with a Contraindication for Oral Anticoagulation

Presenter: Vivek Y. Reddy

April 09, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Presentation

Percutaneous Left Atrial Appendage (LAA) Closure for Stroke Prophylaxis in A-fib Patients

Presenter: Vivek Y. Reddy

January 29, 2013

Presentation TCT 2012

Promising LAA Closure Devices and the Structural Heart Team Approach

Presenter: Carlos Pedra

October 25, 2012

Presentation TCT 2012

Case 3: Optimal Transseptal Puncture for LAA Occlusion

Presenter: Brian Whisenant

October 24, 2012

Presentation TCT 2012

The Spectrum of Late Complications of LAA Closure: Device-Specific Mechanisms, Incidence, and Prevention

Presenter: Peter Block

October 23, 2012

Presentation TCT 2012

Synthesis of the New ESC LAA Closure Guidelines

Presenter: Peter Sick

October 23, 2012

Presentation TCT 2012

Quality-of-Life and Cost-Effectiveness After LAA Closure

Presenter: Vivek Reddy

October 23, 2012

Presentation TCT 2012

Lifetech LAA Closure Device: Description and Preclinical Results

Presenter: Yat-Yin Lam

October 23, 2012

Presentation TCT 2012

LAA Closure in Anticoagulation Contraindicated Patients: The ASAP Trial and Beyond

Presenter: Horst Sievert

October 23, 2012

Presentation TCT 2012

ICE Guidance for LAA Closure: Advantages and Limitations

Presenter: Vivek Reddy

October 23, 2012

Presentation TCT 2012

How to Become Trained and Start a LAA Closure Program

Presenter: Brian Whisenant

October 23, 2012

Presentation TCT 2012

Cardia LAA Closure Device: Description and Preclinical Results

Presenter: Juan Granada

October 23, 2012

Presentation TCT 2012

Attributes of the Perfect LAA Closure Device: What All the Companies Should Strive For

Presenter: Horst Sievert

October 23, 2012

Advertisement

Transcatheter Closure of Incomplete Left Atrial Appendage Occlsuion (Previous Watchman LAA Occluder) - Implantation of a 2nd Generation ACP (Amulet) Device

Ad-hoc TAVI, Ad-hoc Coronary Stenting, and Ad-hoc LAA Closure

LAA Closure Devices - Technique Description and Emerging Data

Percutaneous LAA Closure with the Amplatzer Cardiac Plug in Patients with Nonvalvular A-fib and Contraindications for Anticoagulation Therapy

PROTECT AF: The Mortality Effects of LAA Closure vs. Warfarin for Stroke Prophylaxis in A-fib

LAA Closure for Nonvalvular Atrial Fibrillation

LAA Closure with the Watchman Device in Patients with a Contraindication for Oral Anticoagulation

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Percutaneous Left Atrial Appendage (LAA) Closure for Stroke Prophylaxis in A-fib Patients

Promising LAA Closure Devices and the Structural Heart Team Approach

Case 3: Optimal Transseptal Puncture for LAA Occlusion

The Spectrum of Late Complications of LAA Closure: Device-Specific Mechanisms, Incidence, and Prevention

Synthesis of the New ESC LAA Closure Guidelines

Quality-of-Life and Cost-Effectiveness After LAA Closure

Lifetech LAA Closure Device: Description and Preclinical Results

LAA Closure in Anticoagulation Contraindicated Patients: The ASAP Trial and Beyond

ICE Guidance for LAA Closure: Advantages and Limitations

How to Become Trained and Start a LAA Closure Program

Cardia LAA Closure Device: Description and Preclinical Results

Attributes of the Perfect LAA Closure Device: What All the Companies Should Strive For

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content